Mark Udell - 01 Jan 2018 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)

Role: Chief Accounting Officer
Signature: /s/ Mark Udell
Issuer symbol: AVRW
Transactions as of: 01 Jan 2018
Transactions value $: $0
Form type: 4
Filing time: 27 May 2021, 19:40:19 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVRW	Stock Option	Award	$0	+150,000		$0	150,000	01 Jan 2018	Common Stock	150,000	$0.74	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option becomes exercisable on the basis determined by the equity incentive plan with 6.25% of the option vesting on the first quarter anniversary of vesting start date. For each additional quarter of the participant's service the option will continue to vest until the vested ratio is 100%. This late filing is due to an inadvertent administrative error and not any error of the reporting person.

Content

The option becomes exercisable on the basis determined by the equity incentive plan with 6.25% of the option vesting on the first quarter anniversary of vesting start date. For each additional quarter of the participant's service the option will continue to vest until the vested ratio is 100%. This late filing is due to an inadvertent administrative error and not any error of the reporting person.